Transfusion in lung transplantation is common, and despite improved techniques and limitations in the use of mechanical circulatory support (MCS), the incidence of massive transfusion has remained stable over the years. The consequences of blood transfusion (blood cells, plasma, platelet concentrates) are deleterious for patients and increase primary graft dysfunction and mortality risk. Whole blood viscoelastic testing devices have shown its effectiveness in monitoring coagulation and fibrinolytic function during cardiac surgery, liver transplantation or trauma. So far, few delocalized biology tools have been evaluated in lung transplantation. The main objective of this study is to determine if the use of a transfusion algorithm based on whole blood viscoelastic test with Quantra® test reduce transfusion during lung transplantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
128
The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
Foch Hospital
Suresnes, France
Labile blood products measure
Number of labile blood products (red blood cells pack + fresh frozen plasma) transfused in the operating room.
Time frame: 24 hours
The impact of Quantra® on the administration of each type of transfusion during surgery and within 24 hours after transplantation
Number of patients receiving each type of labile blood product and the number of red blood cell pack, platelet concentrates, fresh frozen plasma, and fibrinogen administered during surgery and within 24 hours following surgery
Time frame: 24 hours
blood loss during surgery
volume of blood lost during surgery.
Time frame: 24 hours
The occurrence of acute primary graft dysfunction at day 3.
Grade 3 primary graft dysfunction measured on the 3rd postoperative day
Time frame: 3 days
Quality of life six months after surgery using EQ-5D-5L questionnaire including five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression
Quality of life questionnaire assement using the EuroQol Group's five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) including five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Time frame: 6 months
Hospital mortality, at 30 days, 90 days, and 12 months
Hospital mortality rate, at 30 days, 90 days, and at 12 months.
Time frame: 12 months
Number of transfused labile blood products during the length of an individual's stay in hospital
The number of transfused labile blood products will evaluated during the length of an individual's stay in hospital
Time frame: up to 12 months
Duration of stay in intensive care
The duration of stay in intensive care will evaluated during the length of an individual's stay in hospital
Time frame: up to 12 months
The median cost of transfused labile blood products
The median cost of transfused labile blood products will evaluated during the length of an individual's stay in hospital
Time frame: up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.